Status:
COMPLETED
Study Of Perennial Allergic Rhinitis In Pediatrics
Lead Sponsor:
GlaxoSmithKline
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
All Genders
3-14 years
Phase:
PHASE3
Brief Summary
To verify of cetirizine dry syrup to ketotifen dry syrup in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Children with perennial allergic rhinitis.
- Giving informed consent.
- Children with a positive response to specific IgE antibody test.
- Children assessed as positive in the nasal eosinophil count.
- Children whose severity score of nasal symptom is 4 or higher.
- Exclusion criteria:
- have spastic disease such as epilepsy
- have a history of drug hypersensitivity
- are pregnant, lactating or possibly pregnant female Children
- are sensitive to pollen as a duplicate allergen and whose treatment periods are thought in the pollen dispersion periods
- have vasomotor rhinitis and eosinophilic rhinitis
- have asthma that requires the treatment with corticosteroid
- have inappropriate complication of nasal disorder that may influence on the evaluation of the study drugs
- have complicated with atopic dermatitis or urticaria that requires the treatment with antihistamine preparation
- have started specific desensitization treatment or nonspecific modulation treatment but who have not reached the maintenance level of treatment
- have received surgical treatment for reduction and modulation of nasal mucosa
- redintegration therapy of nasal cavity to improve the degree of nasal airway
- surgical operation to improve rhinorrhea.
Exclusion
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT00253058
Start Date
July 1 2005
Last Update
May 6 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site